CLRM-01 SUMMARY OF VIRTUAL TUMOR BOARD PLATFORMS AND IMPLEMENTATION IN NEURO-ONCOLOGY. (5th August 2022)

• Record Type: Journal Article
• Authors: Ekhator, Chukwuyem; Kesari, Santosh; Tadipatri, Ramya; Fonkem, Ekokobe; Grewal, Jai
• Is Part Of: Neuro-oncology advances. Volume 4(2022)Supplement 1
• Page Start: i6
• Page End: i6
• Publication Date: 2022-08-05
• Subjects: 616.99481
• DOI: 10.1093/noajnl/vdac078.022
• Languages: English
• ISSNs: 2632-2498

Abstract

Abstract: OBJECTIVE: To report a summary of a systematic review of virtual tumor boards and their implementation in neuro- oncology. BACKGROUND: Virtual tumor board [VTB] platforms are an important aspect of cancer management. They enable easier access to a multidisciplinary team of experts. VTBs are an emerging resource across various cancer care networks in the United States. DESIGN/METHODS: We performed a systematic search of all VTBs incorporating a platform designed for this specific role. We reviewed UC Davis Health Care Center VTB, Genomet, Oncolens, Navify Tumor Board, Medical University of South Carolina Virtual Tumor Board, Precision Oncology, Cancer Commons, Virtual Tumor Board, Virtual Tumor Board Tahoe Forest Cancer Center and MassiveBio. Summary data examined include year of launch, demographics, characteristics of cases, average response time, advantages, and how they handle protected health information. RESULTS: 30% of all VTBs examined launched in 2017. All had a HIPAA compliant online environment. Genomet VirtualBoard de-identifies all patient information; this is a virtual platform primarily focused on neuro-oncology cases. Cases involved a median of 5 specialists most commonly neuro-oncologists, neurosurgeons, radiation oncologists, molecular pathologists and neuroradiologists. Participants had an average of 23 cases reviewed. Case review revealed an age range from 6 months to 84 years [mean age 44.5 years] with 69.6% males and 30.4% females, 43.5% glioblastoma, 8.7% adenocarcinoma, 8.7% infratentorial tumor, <5% each: pineoblastoma, melanoma, hemangioblastoma and pilocytic astrocytoma. Average response time observed in all cases was ≤24 hours. Detailed metrics for numbers/percentages of brain tumor cases were not available for most other platforms at time of submission. This will be updated at presentation. CONCLUSIONS: VTBs have allowed for quicker expert analysis of cases. This has resulted in an accelerated number of cases reviewed with a shortened communication time. More studies are needed to gain additional insight into user engagement metrics.